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While factors associated with receipt of human papillomavirus
(HPV) vaccination have been well characterized, less is known
about the characteristics associated with parents’ intent to have
their adolescent children vaccinated. This study aimed to examine
factors associated with parental intention toward HPV vaccination.
Methods
We analyzed data on 10,354 adolescents aged 13 to 17 years from
the 2014 National Immunization Survey–Teen. Weighted mul-
tivariable logistic regression was used to examine associations
between sociodemographic characteristics of mothers and adoles-
cents, as well as a health care provider recommendation with par-
ents’ intention to have their children receive HPV vaccine.
Results
Among unvaccinated adolescents, Hispanic ethnicity (boys adjus-
ted  odds  ratio  [AOR],  1.87,  95%  confidence  interval  [CI],
1.34–2.61; and girls AOR, 1.57; 95% CI, 1.05–2.35), mothers with
less  than  a  high  school  diploma  (boys  AOR,  2.41;  95%  CI,
1.58–3.67; and girls AOR, 1.86; 95% CI, 1.02–3.38), and having a
health care provider recommend the vaccine (boys AOR, 1.87;
95% CI,  1.52–2.31;  and girls  AOR, 1.38;  95% CI,  1.05–1.82)
were significantly associated with parents’ intention to have their
adolescent child vaccinated within the next 12 months. In addition,
non-Hispanic black race was a significant predictor of parents’ in-
tent to vaccinate for boys (AOR, 1.89; 95% CI, 1.35–2.65).
Conclusion
Maternal education and Hispanic ethnicity were the strongest pre-
dictors of parental intent to vaccinate against HPV, followed by
provider recommendation. As HPV vaccination rates in the United
States remain below the Healthy People 2020 goal, messages may
need to be targeted based on maternal education, race/ethnicity,
and provider recommendation.
Introduction
Nearly all sexually active adults in the United States will acquire
human papillomavirus (HPV) infection during their lifetime (1). If
infection with a high-risk HPV strain persists beyond 1 to 2 years,
anogenital cancers (cervical, penile, and anal cancer) can result
(2).  Incidence of  HPV-associated cancer  is  disproportionately
higher among African Americans, Hispanics, and those living in
poverty (3).
The Advisory Committee on Immunization Practices (ACIP) re-
commends routine HPV vaccination for US adolescents aged 11
and 12 years (4), with catch-up vaccination through age 26 (4).
Despite a Healthy People 2020 goal  of  80% vaccine coverage
among US adolescents (5), the 2014 National Immunization Sur-
vey–Teen (NIS-Teen) survey found that only 60.0% of girls and
41.7% of boys aged 13 to 17 years received at least 1 dose of the
vaccine (6). Moreover, only 39.7% of girls and 21.6% of boys
completed the vaccine series (6); at the time data were collected, 3
doses  of  vaccine  were  required  to  complete  the  HPV vaccine
series (7). This suboptimal uptake is attributed to a lack of physi-
cian recommendation, safety concerns, and inadequate knowledge
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about HPV (8–12). In the United States, the Patient Protection and
Affordable Care Act now requires that all insurance plans cover
the cost of ACIP-recommended vaccines, including HPV vaccine
(13). The Vaccines for Children program provides HPV vaccina-
tion at no cost for underinsured and uninsured children younger
than 19 years (14).
While factors associated with receipt of HPV vaccination are well
characterized, less is known about characteristics associated with
parental intent to have their children vaccinated against HPV. This
understanding is necessary when considering progression across
the stages of health behavior change, as described by the Transthe-
oretical Model (15). Intent — or preparation — occurs when a
person makes the decision to engage in a behavior (eg, HPV vac-
cination) but has not yet taken action. Preparation follows contem-
plation, where the person considers the options (eg, HPV vaccina-
tion vs no HPV vaccination). Understanding factors associated
with intent to have adolescents receive HPV vaccination can in-
form interventions designed to move parents through the stages of
change, from considering HPV vaccination for their adolescents to
intention to vaccinate to actual vaccination. To the best of our
knowledge, no national studies have examined predictors of HPV
vaccination intent. Thus, we used NIS-Teen 2014 data to examine




The NIS-Teen is  an  annual  cross-sectional  survey that  uses  2
phases of data collection to obtain vaccination information from a
national probability sample of parents and guardians of US adoles-
cents  (16,17).  In  the  first  phase  of  data  collection,  a  random-
digit–dialed landline and cellular telephone survey is conducted to
identify households with children aged 13 to 17 years. Parents
provide information about their children’s sociodemographic char-
acteristics, vaccination history, and health care providers. In the
second phase, a Provider Record Check is sent to all identified
providers to obtain provider-verified vaccination records for each
respondent (17). The landline and the cellular telephone response
rates for 2014 were 60.3% and 31.2%, respectively. Because the
NIS-Teen 2014 data set is publicly available, the Saint Louis Uni-
versity institutional review board determined that this project did
not constitute human subjects research.
Measures
NIS-Teen 2014 captured vaccination information for 38,703 eli-
gible  adolescent  boys and girls  aged 13 to 17 years  in  United
States.  Of  these,  21,057 adolescents  (10,866 boys and 10,191
girls)  had adequate provider-verified vaccination records.  Our
study was limited to parents of 10,354 adolescents (4,047 [39.7%]
boys and 6,307 [60.3%] girls) with adequate provider-verified
vaccination records who had not received any dose of HPV vac-
cine and whose parents were subsequently asked about their inten-
tion to have their child vaccinated against HPV in the 12 months
following the survey.
The primary outcome of interest was intention to receive HPV
vaccine, as ascertained from the survey question “How likely is it
that teen will receive HPV shots in next 12 months?” Response
options  included  “very  likely,”  “somewhat  likely,”  “not  too
likely,” “not likely at all,” and “not sure/don’t know.” For the pur-
pose of this analysis, intention to receive HPV vaccine was dicho-
tomized into “likely” and “not likely.” The 574 respondents (par-
ents of 386 [7.6%] boys and 188 [6.1%] girls) who answered “not
sure/don’t know” were excluded; however, a subanalysis of these
parents (“not sure/don’t know” vs all other categories) was also
conducted.
Adolescent sociodemographic covariates were sex, race/ethnicity
(non-Hispanic white, non-Hispanic black, Hispanic, or non-His-
panic other [including multiple races/ethnicities]), and poverty
status. Poverty status (above poverty or below poverty) was as-
sessed by comparing respondents’ household income to the US
Census poverty level (18). Because of known geographic vari-
ation in vaccine uptake (19), 4 census regions were used (North-
east,  Midwest,  South, or West).  The adolescent’s mother’s so-
ciodemographic covariates were maternal age (≤34 y, 35–44 y, or
≥45  y),  education  level  (less  than  high  school  diploma,  high
school diploma or general equivalency degree, some college, or
college graduate), marital status (married or never married), and
number of children aged 18 years or younger (1, 2 or 3, or ≥4).
Provider-level covariates were provider recommendation for HPV
vaccination (yes or no) and number of valid, unique health care
providers identified by respondents (1, 2, or ≥3).
Statistical analysis
Differences in characteristics of adolescents were evaluated by us-
ing χ2 tests, stratified by the adolescent’s sex. Weighted multivari-
ate binary logistic regression analyses were performed to examine
the association between adolescents’ sociodemographic character-
istics and the parents’ intention to have them receive HPV vac-
cine in the next 12 months, stratified by the adolescents’ sex. To
test for differences in associations between boys and girls, 2-tailed
z tests were performed by using the estimate and standard errors of
the logistic regression coefficients (log odds ratios). This method
is equivalent to testing for interactions within a single model but
keeps the individual models more interpretable. A second mul-
tivariate logistic regression was conducted to examine factors as-
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sociated with the parental answer, “not sure/don’t know” (about
future HPV vaccination) versus all other categories of intent (ie,
likely or unlikely to vaccinate). All analyses were performed in
SAS version 9.4 (SAS Institute, Inc) and adjusted with weights as
provided in the NIS-Teen 2014 data set to be representative of the
US population. The level of statistical significance for all analyses
was P < .05. To preserve sample size and reduce potential bias,
missing values for explanatory variables were treated as a separ-
ate category in the logistic regression models but were not inter-
preted in the results.
Results
Table 1 presents weighted demographic characteristics of adoles-
cents aged 13 to 17 years who had not received any dose of HPV
vaccine, stratified by sex. Adolescents were largely non-Hispanic
whites living above the poverty level and residing in the South.
Mothers were largely aged 45 years or older, married, and college
graduates. Parents of 30.8% of boys and 53.1% of girls had re-
ceived a health care provider recommendation for HPV vaccina-
tion for their child (P < .001).  Approximately 7% of all survey re-
spondents  responded  “not  sure/don’t  know” for  whether  they
would vaccinate their adolescents for HPV in the next 12 months
(data not shown).
Among unvaccinated boys, variables independently predictive of
intent to vaccinate against HPV were non-Hispanic black race/eth-
nicity (AOR, 1.89; 95% confidence interval [CI], 1.35–2.65) and
Hispanic race/ethnicity (AOR, 1.87; 95% CI, 1.34–2.61) com-
pared with non-Hispanic whites; mothers with less than a high
school diploma (AOR, 2.41; 95% CI, 1.58–3.67) or high school
diploma  or  general  equivalency  degree  (AOR,  1.50;  95% CI,
1.12–2.02) compared with college graduates; never married moth-
ers (AOR, 1.39; 95% CI, 1.06–1.81) compared with married moth-
ers; and a provider recommendation for HPV vaccine (AOR, 1.87;
95% CI, 1.52–2.31) (Table 2). Among unvaccinated girls, predict-
ors of HPV vaccination intention were Hispanic race/ethnicity
(AOR, 1.57; 95% CI, 1.05–2.35) compared with non-Hispanic
whites, mothers with less than a high school diploma (AOR, 1.86;
95% CI, 1.02–3.38) compared with college graduates, and a pro-
vider  recommendation  for  the  vaccine  (AOR,  1.38;  95%  CI,
1.05–1.82). Additionally, mothers with some college education
were more likely to intend to vaccinate their sons (AOR, 1.21;
95% CI, 0.93–1.58) and less likely to intend to vaccinate their
daughters (AOR, 0.69; 95% CI, 0.51–0.94) than were mothers
with a college education.
Characteristics of adolescents whose parents reported that they
were “not sure/don’t know” if they would vaccinate their children
in the next 12 months are presented in Table 3. The largest per-
centage were boys (66.2%), non-Hispanic whites (46.8%), lived in
the South (37.8%), lived above the poverty line (62.3%), had a
college-graduate mother (30.5%), and had never received a recom-
mendation  for  HPV  vaccination  from  a  health  care  provider
(75.2%). Pearson χ2 tests indicated that, compared with those who
expressed their intention about their likelihood to vaccinate their
adolescents, parents who answered “not sure/don’t know” were
significantly different based on adolescent’s race/ethnicity (P =
.001), poverty status (P = .001), mother’s education (P = .003),
and provider recommendation for HPV vaccine (P = .001).
Table 3 also presents multivariate logistic regression analysis of
factors predicting a parental response of “not sure/don’t know”
about intent to have their child vaccinated in the next 12 months.
Parents of adolescent girls were less likely to say “not sure/don’t
know” (AOR, 0.60; 95% CI, 0.42–0.87) than parents of boys. Fur-
thermore, parents of non-Hispanic black adolescents (AOR, 1.90;
95%  CI,  1.13–3.19)  compared  with  parents  of  non-Hispanic
whites and parents of adolescents living below the poverty level
(AOR, 1.77; 95% CI, 1.07–2.92) were more likely to say “not
sure/don’t know.”
Discussion
This secondary analysis of NIS-Teen 2014 data found that among
parents of US adolescents aged 13 to 17 years, maternal education
emerged as the strongest  predictor of  parental  intent  to obtain
HPV vaccination for their children. Although provider recom-
mendation was also a significant predictor of intent to vaccinate,
the  effect  was  not  as  strong  as  maternal  education  and  was
stronger for boys than girls. This differs from what is known about
actual receipt of HPV vaccination, where provider recommenda-
tion is well established as the strongest predictor of actual vaccine
uptake (20). This suggests that different factors may influence in-
tent versus action, which should be acknowledged when consider-
ing interventions to elicit behavior change and progress across the
stages of the Transtheoretical Model (15). For example, education-
al materials designed to increase awareness and understanding of
HPV vaccination target  people at  the early stages of  behavior
change (ie, precontemplation and contemplation). Provider recom-
mendation affects action — the initiation of HPV vaccination.
However, our study indicate that additional factors, such as mater-
nal  education and race/ethnicity,  may be important  targets  for
transitioning to the preparation phase — those who intend to ob-
tain HPV vaccination for their adolescents but have not yet had the
first vaccination administered. Additionally, some targets for inter-
vention may vary by the adolescent’s sex: mother’s marital status
and non-Hispanic black race/ethnicity were significant predictors
of intention to obtain HPV vaccination for parents of adolescent
boys but not girls.
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The lower intent to have their child vaccinated among college-
educated mothers and parents of non-Hispanic white adolescents
may be counterintuitive, because people from racial/ethnic minor-
ity groups and those with fewer economic resources often have
challenges with access to medical care and uptake of medical ser-
vices (21). However, these findings are consistent with previous
research that found an association between the refusal of all child-
hood vaccines and white, college-educated mothers and high-in-
come parents (22). Other studies also show higher rate of HPV
vaccination among low-income and minority adolescents (19,23).
A possible explanation for this phenomenon could be that daugh-
ters of above-poverty, non-Hispanic white parents have greater ac-
cess to routine medical care, possibly leading to a lowered per-
ceived need for HPV vaccine (21). Additionally, higher cervical
cancer incidence and mortality among black and Hispanic minorit-
ies (3,24) may translate to a greater perceived susceptibility for
HPV infection and a greater perceived need for preventive meas-
ures, such as HPV vaccination, than among non-Hispanic whites.
A recent study supports this hypothesis, showing that maternal ex-
periences with HPV-related disease have been associated with
greater willingness to vaccinate their adolescents against HPV
(25).
Our findings indicated some effect size differences among boys
and girls in which parental intent to vaccinate was stronger for
boys than for girls in the same category. For example, mothers
with some college education were more likely to intend to vaccin-
ate their sons and less likely to intend to vaccinate their daughters
than mothers who were college graduates. Research suggests that
parenting roles may be more protective of adolescent daughters
than adolescent sons. This may be due in part to parents’ concerns
about the unique risks for adolescent girls (eg, unwanted sexual in-
volvement, pregnancy) (26). Several studies reported an opposi-
tion to vaccination of young girls, specifically for HPV, out of the
unfounded fear that vaccination could have unwanted or negative
influences on young girls’ sexual behavior (27,28). This attitude is
fueled by 2 main theories: 1) that HPV vaccination may “ignite
curiosity” leading to premature sexual activity because girls may
believe that the vaccine will provide protection against all sexu-
ally transmitted infections (26) and 2) that parental consent for the
HPV vaccine may imply parental approval of sexual activity (29).
These ideas have been proven untrue in numerous studies; vaccin-
ation against HPV does not encourage risky sexual behavior and
has actually been shown to support delayed sexual activity be-
cause of adolescents’ exposure to health information during the
HPV vaccination (26). This coexistence of scientifically proven
evidence and the continued presence and proliferation of incorrect
ideas reinforces the need for provider involvement and recom-
mendation of HPV vaccine. This approach can aid in overcoming
any potential incorrect assumptions among parents of adolescents.
The importance of provider recommendation for HPV vaccination
is  consistent  with  earlier  research  that  suggests  this  to  be  the
strongest  predictor of HPV vaccine receipt  (20,23).  Our study
found that a large percentage (75.2%) of respondents answering
“not sure/don’t know” about their intent to vaccinate their adoles-
cents in the next 12 months had never had a health care provider
recommend the vaccination. Clinicians are a trusted source and fa-
cilitator of vaccination behavior for all race/ethnicities (23). Thus,
because such a large percentage of parents answering “not sure/
don’t know” had not received a provider recommendation for the
vaccine, it is not surprising that they remain on the fence about
their intent to vaccinate their adolescents. Provider recommenda-
tion could be modified by interventions that target parental de-
cision making along the stages of change continuum. Parents in
the precontemplation and contemplation stages of HPV vaccina-
tion (such as those whose intent to vaccinate is “not sure/don’t
know”)  will  need  different  tailored  messages  and discussions
about the vaccine with clinicians. Current strategies to encourage
providers to recommend HPV vaccination should be evaluated for
effectiveness, and additional research is needed to better under-
stand the quality of provider recommendation and how that dif-
fers by sociodemographic characteristics of adolescents. Addition-
al research may also be needed to better understand the perceived
barriers that clinicians report (30,31,32) to delivering HPV-re-
lated information and messages to patients at the different stages
of decision making.
Approximately 7% of all survey respondents responded “not sure/
don’t know” for whether they would vaccinate their adolescents
for HPV in the next 12 months. Our analysis indicated that par-
ents of adolescent boys and non-Hispanic blacks and parents liv-
ing below the poverty line were more likely to remain undecided
about their intention to have their children vaccinated. This may
be attributed to the lower awareness of HPV and HPV vaccine
among non-Hispanic black women and those living below the
poverty line (33). While this is a small subset of the sample over-
all, it is important to consider that individuals who are in the pre-
contemplation stage of decision making may benefit from differ-
ent intervention strategies than those who are in the contemplation
or preparation stages of change. Further research to examine atti-
tudes  toward HPV vaccine  and beliefs  of  precontemplators  is
needed to inform development of interventions aimed at increas-
ing HPV vaccine uptake.
A strength of this study is that it used a provider-verified vaccina-
tion history of a large, nationally representative sample of US ad-
olescents. This reduces the potential for recall bias and social de-
sirability bias with respect to parents reporting their child’s HPV
vaccine status. However, this study also has a several limitations.
Because of the cross-sectional nature of the data, causality cannot
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be determined, and temporal interpretations are limited. Second,
although statistical adjustments were made to account for nonre-
sponse and households without telephones, a possibility of nonre-
sponse bias still exists. Our analysis was limited to the informa-
tion included in NIS-Teen; therefore, we were not able to account
for other factors associated with parental intention for HPV vac-
cination, such as personal or family history of gynecological can-
cer and sexually transmitted diseases, which have been shown to
be positively associated with parental intention toward adoles-
cents’ vaccination (34). Lastly, NIS-Teen does not conduct a fol-
low-up survey to determine if those who intended to obtain HPV
vaccination for their adolescents actually initiated and completed
the vaccine series.
This study highlights several differences in parental intention to-
ward HPV vaccination based on adolescents’ sociodemographic
characteristics and the receipt of provider recommendation for
HPV vaccination. Interventions should consider maternal educa-
tion attainment, and studies should seek to understand why adoles-
cents whose mothers have a college degree are not likely to intend
to have their children vaccinated. Additionally, health care pro-
viders should actively engage in discussions with parents about
HPV and strongly recommend the vaccine to all eligible patients
concurrently with other routinely administered vaccinations to dis-
pel any potential negative assumptions or opinions regarding HPV
vaccination,  especially  among girls.  Tailored efforts  could be
made to providers who serve different communities,  primarily
those who serve non-Hispanic  whites,  particularly  those from
high-income households or with mothers with college degrees.
Additional studies are needed to examine provider–patient interac-
tions  in  these  settings  to  better  understand how to  effectively
frame those efforts.
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Tables
Table 1. Characteristics of Adolescents Aged 13 to 17 Years Not Vaccinated Against Human Papillomavirus (HPV), by Sex, National Immunization Survey–Teen,
2014
Variable Boys (n = 4,047), n (Weighted %)a Girls (n = 6,307), n (Weighted %)a P Valueb
Age, y
13 1,330 (21.9) 1,046 (25.1)
.03
14 1,297 (20.4) 913 (21.9)
15 1,244 (18.0) 729 (18.9)
16 1,290 (21.8) 711 (17.9)
17 1,146 (18.0) 648 (16.1)
Race/ethnicity
Non-Hispanic white 4,446 (60.7) 2,737 (58.0)
.34
Non-Hispanic black 527 (12.7) 356 (12.0)
Hispanic 784 (18.1) 522 (19.8)
Non-Hispanic otherc 550 (8.5) 432 (10.2)
Census region
South 2,329 (40.0) 1,458 (39.3)
.98
Midwest 1,452 (23.3) 920 (23.8)
Northeast 1,015 (14.8) 661 (14.8)
West 1,511 (22.0) 1,008 (22.1)
Poverty statusd
Above poverty level 5,155 (74.4) 3,325 (76.6)
.27Below poverty level 925 (21.0) 563 (23.4)
Unknown 227 (4.6) 159 (3.5)
Mother’s education
Less than high school diploma 580 (11.3) 365 (12.3)
.87
High school diploma or general equivalency
degree
1,101 (23.6) 722 (23.8)
Some college 1,770 (26.9) 1,170 (26.9)
College graduate 2,856 (38.1) 1,790 (37.0)
Mother’s marital status
Married 4,810 (68.8) 3,081 (70.6)
.34
Never married 1,497 (31.2) 966 (29.4)
Mother’s age, y
≤34 407 (7.0) 289 (8.1)
.2335–44 2,585 (45.8) 1,640 (42.9)
a All percentages were weighted with RDDWT_D sampling weight provided in National Immunization Survey–Teen, 2014.
b P values calculated by χ2.
c Includes multiracial and multiethnic.
d Based on the US Census poverty levels.
(continued on next page)
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Table 1. Characteristics of Adolescents Aged 13 to 17 Years Not Vaccinated Against Human Papillomavirus (HPV), by Sex, National Immunization Survey–Teen,
2014
Variable Boys (n = 4,047), n (Weighted %)a Girls (n = 6,307), n (Weighted %)a P Valueb
≥45 3,315 (47.2) 2,118 (50.0)
Number of mother’s children aged <18 y
1 2,519 (33.1) 1,543 (31.5)
.162 or 3 3,164 (54.4) 2,043 (53.5)
≥4 624 (12.4) 461 (15.0)
Number of health care providers
1 3,233 (53.3) 2,048 (50.7)
.412 1,879 (28.3) 1,207 (29.7)
≥3 1,177 (18.3) 785 (19.6)
Health care provider recommended HPV vaccine
Yes 2,146 (30.8) 2,230 (53.1)
<.001No 4,061 (67.2) 1,740 (44.4)
Missing 100 (1.9) 77 (2.4)
Parent intends to have child receive HPV vaccine in next 12 months
Not likely 3,343 (54.5) 2,006 (51.5)
.08Likely 1,258 (37.9) 1,485 (42.4)
Not sure/don’t know 386 (7.6) 188 (6.1)
a All percentages were weighted with RDDWT_D sampling weight provided in National Immunization Survey–Teen, 2014.
b P values calculated by χ2.
c Includes multiracial and multiethnic.
d Based on the US Census poverty levels.
PREVENTING CHRONIC DISEASE VOLUME 14, E45
PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY           JUNE 2017
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
8       Centers for Disease Control and Prevention  •  www.cdc.gov/pcd/issues/2017/16_0314.htm
Table 2. Association Between Characteristics of Adolescents Aged 13 to 17 Years and Intent to Receive Human Papillomavirus (HPV) Vaccine in the Next 12
Months, by Sex, National Immunization Survey–Teen, 2014a
Variable
Intends to Receive HPV Vaccine
Interaction P ValuebOverall AOR (95% CI) Boys AOR (95% CI) Girls AOR (95% CI)
Sex
Boys 1 [Reference] —
Girls 1.06 (0.90–1.26) —
Age, y
13 1 [Reference] 1 [Reference] 1 [Reference] —
14 0.93 (0.72–1.19) 1.11 (0.80–1.53) 0.71 (0.50–1.02) .07
15 0.89 (0.70–1.14) 0.83 (0.61–1.12) 1.01 (0.69–1.48) .41
16 1.02 (0.79–1.32) 1.08 (0.77–1.51) 0.92 (0.63–1.33) .52
17 0.74 (0.57–0.97) 0.83 (0.60–1.15) 0.64 (0.43–0.97) .35
Race/ethnicity
Non-Hispanic white 1 [Reference] 1 [Reference] 1 [Reference] —
Non-Hispanic black 1.63 (1.24–2.15) 1.89 (1.35–2.65) 1.30 (0.83–2.04) .19
Hispanic 1.69 (1.29–2.20) 1.87 (1.34–2.61) 1.57 (1.05–2.35) .52
Non-Hispanic otherc 1.27 (0.93–1.75) 1.18 (0.74–1.89) 1.42 (0.95–2.12) .56
Census region
South 1 [Reference] 1 [Reference] 1 [Reference] —
Midwest 0.96 (0.80–1.15) 0.98 (0.77–1.23) 0.92 (0.68–1.23) .74
Northeast 0.99 (0.80–1.23) 1.13 (0.86–1.48) 0.77 (0.55–1.08) .08
West 0.99 (0.75–1.29) 1.02 (0.73–1.41) 0.92 (0.60–1.43) .73
Poverty statusd
Above poverty 1 [Reference] 1 [Reference] 1 [Reference] —
Below poverty 1.15 (0.88–1.50) 0.92 (0.67–1.26) 1.53 (1.00–2.35) .06
Mother’s education
Less than high school diploma 2.11 (1.48–2.99) 2.41 (1.58–3.67) 1.86 (1.02–3.38) .49
High school diploma or general
equivalency degree
1.25 (1.01–1.59) 1.50 (1.12–2.02) 0.97 (0.69–1.38) .06
Some college 0.97 (0.79–1.19) 1.21 (0.93–1.58) 0.69 (0.51–0.94) .006
College graduate 1 [Reference] 1 [Reference] 1 [Reference] —
Mother’s marital status
Married 1 [Reference] 1 [Reference] 1 [Reference] —
Never married 1.37 (1.12–1.69) 1.39 (1.06–1.81) 1.33 (0.97–1.82) .84
Abbreviations: —, not applicable; AOR, adjusted odds ratio; CI, confidence interval.
a All percentages were weighted with RDDWT_D sampling weight provided in the National Immunization Survey–Teen, 2014. The models for both boys and girls
were adjusted for all variables included in the table.
b P values calculated by logistic regression.
c Includes multiracial and multiethnic.
d Based on the US Census poverty levels.
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Table 2. Association Between Characteristics of Adolescents Aged 13 to 17 Years and Intent to Receive Human Papillomavirus (HPV) Vaccine in the Next 12
Months, by Sex, National Immunization Survey–Teen, 2014a
Variable
Intends to Receive HPV Vaccine
Interaction P ValuebOverall AOR (95% CI) Boys AOR (95% CI) Girls AOR (95% CI)
Mother’s age, y
≤34 1 [Reference] 1 [Reference] 1 [Reference] —
35–44 1.20 (0.88–1.63) 1.41 (0.93–2.13) 0.93 (0.58–1.49) .20
≥45 1.22 (0.88–1.70) 1.44 (0.94–2.21) 0.99 (0.60–1.64) .27
Number of mother’s children aged <18 y
1 1 [Reference] 1 [Reference] 1 [Reference] —
2 or 3 1.01 (0.84–1.23) 0.88 (0.70–1.11) 0.88 (0.70–1.11) .06
≥4 0.63 (0.45–0.87) 0.74 (0.49–1.10) 0.50 (0.30–0.84) .25
Number of health care providers
1 1 [Reference] 1 [Reference] 1 [Reference] —
2 1.15 (0.95–1.38) 1.08 (0.85–1.36) 1.24 (0.93–1.66) .45
≥3 1.10 (0.88–1.38) 1.05 (0.79–1.39) 1.24 (0.88–1.74) .45
Health care provider recommended HPV vaccine
No 1 [Reference] 1 [Reference] 1 [Reference] —
Yes 1.63 (1.38–1.93) 1.87 (1.52–2.31) 1.38 (1.05–1.82) .08
Abbreviations: —, not applicable; AOR, adjusted odds ratio; CI, confidence interval.
a All percentages were weighted with RDDWT_D sampling weight provided in the National Immunization Survey–Teen, 2014. The models for both boys and girls
were adjusted for all variables included in the table.
b P values calculated by logistic regression.
c Includes multiracial and multiethnic.
d Based on the US Census poverty levels.
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Table 3. Characteristics of Adolescents Aged 13 to 17 Years and Multivariable Logistic Regression Predicting Parents’ Answering “Not Sure/Don’t Know” About
Their Intention to Vaccinate Their Adolescents Against Human Papillomavirus (HPV) in the Next 12 Months, National Immunization Survey–Teen, 2014a
Variable
Known HPV Vaccine Intent (All
Other Categories), n (Weighted
%)
Unknown HPV Vaccine Intent
(Not Sure/Don’t Know), n
(Weighted %) P Valueb
Likelihood of Saying Not Sure/
Don’t Know About HPV Vaccine
Intention, AOR (95% CI)
Overall 8,992 (93.0) 574 (7.0) — —
Adolescent’s sex
Female 3,491 (39.3) 188 (33.8)
.22
0.60 (0.42–0.87)
Male 5,501 (60.7) 386 (66.2) 1 [Reference]
Adolescent’s age, y
13 2,102 (23.8) 133 (20.9)
.69
1 [Reference]
14 1,923 (21.1) 124 (19.6) 1.26 (0.71–2.25)
15 1,731 (18.3) 115 (21.4) 1.20 (0.65–2.22)
16 1,707 (20.0) 119 (22.8) 1.24 (0.66–2.34)
17 1,529 (16.8) 83 (15.3) 1.17 (0.61–2.25)
Adolescent’s race/ethnicity
Non-Hispanic white 6,369 (61.8) 337 (46.8)
.001
1 [Reference]
Non-Hispanic black 718 (11.6) 70 (15.2) 1.90 (1.13–3.19)
Hispanic 1,097 (18.3) 77 (20.4) 1.60 (0.89–2.87)
Non-Hispanic otherc 808 (9.0) 90 (17.6) 1.83 (1.11–3.02)
Census region
South 3,249 (39.8) 225 (37.8)
.09
1 [Reference]
Midwest 2,102 (24.2) 102 (17.6) 1.07 (0.69–1.67)
Northeast 1,445 (14.60 124 (20.3) 1.56 (1.00–2.43)
West 2,196 (21.4) 123 (23.3) 1.01 (0.53–1.92)
Poverty statusd
Above poverty 7,503 (76.6) 409 (62.3)
.001
1 [Reference]
Below poverty 1,169 (19.4) 129 (30.5) 1.77 (1.07–2.92)
Unknown 320 (4.0) 36 (7.2) —
Mother’s education
Less than high school diploma 729 (10.2) 93 (18.5)
.003
1.61 (0.77–3.39)
High school diploma or general
equivalency degree
1,524 (23.1) 122 (26.9) 1.21 (0.72–2.04)
Some college 2,591 (27.5) 160 (24.0) 1.26 (0.83–1.92)
College graduate 4,148 (39.2) 199 (30.5) 1 [Reference]
Mother’s marital status
Abbreviations: —, not applicable; AOR, adjusted odds ratio; CI, confidence interval.
a All percentages were weighted with RDDWT_D sampling weight provided in the National Immunization Survey–Teen, 2014. The model was adjusted for all vari-
ables included in the table.
b P value of Pearson χ2 test indicating the difference in sociodemographic characteristics between respondents who answered “not sure/don’t know” versus all
other categories of intent (ie, likely or unlikely to vaccinate) about their intention to vaccinate their adolescents in the next 12 months.
c Includes multiracial and multiethnic.
d Based on the US Census poverty levels.
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Table 3. Characteristics of Adolescents Aged 13 to 17 Years and Multivariable Logistic Regression Predicting Parents’ Answering “Not Sure/Don’t Know” About
Their Intention to Vaccinate Their Adolescents Against Human Papillomavirus (HPV) in the Next 12 Months, National Immunization Survey–Teen, 2014a
Variable
Known HPV Vaccine Intent (All
Other Categories), n (Weighted
%)
Unknown HPV Vaccine Intent
(Not Sure/Don’t Know), n
(Weighted %) P Valueb
Likelihood of Saying Not Sure/
Don’t Know About HPV Vaccine
Intention, AOR (95% CI)
Married 6,918 (70.4) 411 (63.3)
.09
1 [Reference]
Never married 2,074 (29.6) 163 (36.6) 1.00 (0.66–1.52)
Mother’s age, y
≤34 595 (7.2) 48 (11.0)
.11
1 [Reference]
35–44 3,655 (45.0) 245 (38.8) 0.83 (0.47–1.47)
≥45 4,742 (47.8) 281 (50.2) 1.26 (0.64–2.51)
Number of mother’s children aged <18 y
1 3,513 (32.4) 234 (34.3)
.74
1 [Reference]
2 or 3 4,545 (54.2) 268 (51.1) 1.04 (0.69–1.59)
≥4 934 (13.3) 72 (14.6) 0.93 (0.51–1.72)
Number of health care providers
1 4,559 (52.1) 326 (53.7)
.27
1 [Reference]
2 2,693 (28.9) 172 (32.4) 1.31 (0.87–1.96)
≥3 1,740 (19.0) 76 (13.8) 0.93 (0.57–1.51)
Health care provider recommended HPV vaccine
No 5,227 (60.8) 426 (75.2)
.001
1 [Reference]
Yes 3,765 (39.2) 148 (24.8) 0.81 (0.54–1.21)
Abbreviations: —, not applicable; AOR, adjusted odds ratio; CI, confidence interval.
a All percentages were weighted with RDDWT_D sampling weight provided in the National Immunization Survey–Teen, 2014. The model was adjusted for all vari-
ables included in the table.
b P value of Pearson χ2 test indicating the difference in sociodemographic characteristics between respondents who answered “not sure/don’t know” versus all
other categories of intent (ie, likely or unlikely to vaccinate) about their intention to vaccinate their adolescents in the next 12 months.
c Includes multiracial and multiethnic.
d Based on the US Census poverty levels.
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